Genmab

	3/11 15:22 af E L	and from Mathai Mammen, when he was still at JNJ, -This study with the HexaBody is being run by Genmab in close collaboration with us. And it's a next generation even more effective CD38 blocker, deep activity on CD38 positive cells. And we'll see data towards the end of this year that'll help us understand whether there's a path forward, both in multiple myeloma, by the way, and diffuse large cell B cell lymphoma. And so, this is exciting for us.
	3/11 15:21 af E L	we knew from JPM conf Jan22; dose escalation data this year, small data maybe this year, but full data '23
	3/11 15:14 af E L	3254 Preliminary Dose-Escalation Results from a Phase 1/2 Study of GEN3014 (HexaBody®-CD38) in Patients (pts) with Relapsed or Refractory Multiple Myeloma (RRMM) (link)
	3/11 15:13 af Solsen	Time will show. Husk det er tidlige data.
	3/11 15:10 af Sukkeralf	....but "only" poster presentation for HexCD38 - is that enough for us to expect convincing data?
	3/11 15:05 af GeorgeBest	4 oral presentations of epco. 19 in total from Genmab
	3/11 15:03 af GeorgeBest	ASH abstracts from Genmab (link)
	3/11 11:58 af Sukkeralf	Quite a big drug Tecvali could become and in line with JNJ projecting >$5 billion.
	3/11 11:57 af Sukkeralf	From the viewpoint also: Besides, experts said they foresee the way being paved for Tecvayli to move into earlier lines of treatment relatively quickly. Analysts from Morgan Stanley pointed out that J&J has trials underway to do just that, and said this helps to bolster the sunny revenue outlook for the company’s multiple myeloma assets, projecting sales of Tecvayli to reach $6.6 billion by 2030 and Carvykti sales to garner $5.7 billion in that same time frame.
	3/11 11:41 af StockBull	Spændende hvad bundlinien bliver på Genmabs q3 regnskab. Gætter på 2.9mia årest første 9 mdr
	3/11 11:25 af Budweis	Jeg øgede kraftigt min eksponering i $HZNP efter tilbagefaldet ovenpå Q2. Godt at se de allerede har fået hånd om situationen. Ikke overraskende at de går ind i Europa. Det har undret mig længe, at de ikke var mere sultne på det globale potentiale for TEPEZZA.
	3/11 11:16 af E L	(link) Horizon Q3 2022 Presentation
	3/11 10:50 af bibob	Although it fell short of response rates shown by its Car-T cell competitors the US approval of J&J ,s Tecvayli on tuesday along with some winning attributes has set it up as a major player in the multiple myeloma treatment paradigm according to key opinion leaders in the field
	3/11 10:49 af StockBull	Har smidt de spekulative her i 2945
	3/11 10:48 af StockBull	Ser godt ud. Så er target på 2969 ved at være i hus
	3/11 10:33 af bibob	ViewPoints: Tecvayli in strong standing as soon - to - be newcomber in heavily pre-treated multiple myeloma.
	3/11 07:44 af ProInvestorNEWS	Dagens mange regnskaber: (link)
	3/11 07:34 af ProInvestorNEWS	Godmorgen :-)
	3/11 07:19 af Stroka	God morgen :-)
	3/11 07:06 af Helge Larsen/PI-redaktør	Godmorgen :-)
	2/11 22:35 af Helge Larsen/PI-redaktør	USA/lukning: Powell sendte aktierne i dørken efter kortvarigt plus (link)
	2/11 21:53 af Bulder	Hm, US dykker kraftigt efter fed. Men både gmab og nvo (ads) holder sig oppe.
	2/11 20:54 af Vitus	Det går helt som ventet…..Genmab er min guldåre….
	2/11 18:23 af Bulder	Hznp oppe med 11%

	2/11 18:07 af gdn55	Vitus, hvordan går det?
	2/11 14:42 af E L	GEN1056 starts recruiting. that is fast. in Moldova... (link)
	2/11 14:41 af E L	i can see no late breaking abstract for SITC
	2/11 14:28 af E L	(link) Novo presentation for Mim8
	2/11 14:28 af E L	market seems to like it, pre market HZNP +8%
	2/11 14:20 af Sukkeralf	Not bad at all
	2/11 13:23 af E L	The Company continues to expect TEPEZZA full-year 2022 net sales percentage growth in the high teens
	2/11 13:20 af E L	Today, the Company announced it is increasing its ex-U.S. peak annual net sales expectations for TEPEZZA to greater than $1 billion from the previous estimate of greater than $500 million, following further assessment of the ex-U.S. TED market opportunity and now also incorporating plans to launch TEPEZZA in Europe. The Company continues to expect U.S. peak annual net sales of greater than $3 billion, bringing global peak annual net sales expectations to greater than $4 billion.
	2/11 13:18 af E L	-- Increasing TEPEZZA Ex-U.S. Peak Annual Net Sales Expectations to Greater than $1 Billion, Bringing Global Peak Annual Net Sales Expectations to Greater than $4 Billion --
	2/11 13:18 af E L	-- TEPEZZA® (teprotumumab-trbw) Net Sales of $490.9 Million -- (link)
	2/11 07:33 af ProInvestorNEWS	Oversigt på dagens mange regnskaber.(link)
	1/11 19:36 af ProInvestorNEWS	Servicemeddelelse: Spændende nyt i Zealand Pharma-chatten.
	1/11 18:39 af bikube	Kursen "sitter fast", er der nogen der kan "åbn dn". (Monrad og Rislund).
	1/11 18:01 af AaBforever	Ok luk..2900
	1/11 17:56 af gdn55	Nå ,undskyld, så er der noget jeg har misforstået.
	1/11 17:47 af Vitus	Jeg ønsker alle mine aktier stiger….jeg er nemlig ikke spekulant…
	1/11 17:42 af gdn55	Det får vi at se. Nogen ønsker den stiger, andre den falder.
	1/11 17:12 af Vitus	Det tror jeg ikke….
	1/11 10:41 af Stroka	Mon ikke vi ser kurs 3000 før regnskab. :-)
	1/11 06:15 af Doublo	Pensionisten jeg ser kun slutkurs 38,51 og laveste handlet 38,28
	31/10 17:38 af E L	'While AbbVie does face several near-term pressures, we believe the firm is making strides with its pipeline, but probably needs to augment internal efforts with increased acquisitions. Within the pipeline, we are bullish on recently filed lymphoma drug epcoritamab.' (link)
	31/10 15:44 af E L	Y-mAbs Therapeutics with many former Genmab employees -49% atm on negative FDA decision on their neuroblastoma drug. (now trading at $4.50, were at $54 end2020...
	31/10 15:07 af Sukkeralf	Hov det var den forkerte tråd
	31/10 14:33 af Sukkeralf	Ikke dårligt for RAPT Therapeutics da RPT193 gerne skulle ende op med en bedre safety profil
	31/10 14:32 af Sukkeralf	(link)
	31/10 07:55 af ProInvestorNEWS	Se ugens mange regnskaber: (link)